Showing 1691-1700 of 2050 results for "".
- Viatris Acquires Oyster Point Pharmahttps://modernod.com/news/viatris-acquires-oyster-point-pharma/2481230/Viatris, a global health care company, announced it is acquiring Oyster Point Pharma, maker of Tyrvaya nasal spray, for $11 per share in cash, plus contingent payments up to $2 per share based on the achievement of specified performance targets. The acquisition of Oyster Point
- Johnson & Johnson Vision Receives Approval in Canada for Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Managementhttps://modernod.com/news/johnson-johnson-vision-receives-approval-in-canada-for-acuvue-abiliti-overnight-therapeutic-lenses-for-myopia-management/2481191/Johnson & Johnson Vision received approval from Health Canada for Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Management. These orthokeratology (ortho-k) lenses are worn overnight for the control of myopia and are specifically designed to match a patient’s eye based on i
- Cellusion and Minaris Regenerative Medicine Enter Alliance for the Manufacturing of Corneal Endothelial Cell Regenerative Therapyhttps://modernod.com/news/cellusion-and-minaris-regenerative-medicine-enter-alliance-for-the-manufacturing-of-corneal-endothelial-cell-regenerative-therapy/2481170/Cellusion, a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem, and Minaris Regenerative Medicine, a global contract and development manufacturing organization, announced a Letter of Intent (LOI) of the Manufacturing of CLS001 for a cor
- PatientPoint Acquires Rendia to Accelerate Expansion into Ophthalmology Specialtyhttps://modernod.com/news/patientpoint-acquires-rendia-to-accelerate-expansion-into-ophthalmology-specialty/2481166/PatientPoint announced the acquisition of Rendia, a provider of point-of-care content for eye care providers sold on a subscription basis. Terms of the deal were not disclosed. With PatientPoint’s expansion into ophthalmology and optometry, PatientPoint’
- Cellusion and Minaris Regenerative Medicine Enter into Business Alliance for the Manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative Therapyhttps://modernod.com/news/cellusion-and-minaris-regenerative-medicine-enter-into-business-alliance-for-the-manufacturing-of-cls001-for-a-corneal-endothelial-cell-regenerative-therapy/2481150/Cellusion, a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem, and Minaris Regenerative Medicine, a global contract and development manufacturing organization, announced a letter of intent (LOI) of the manufacturing of CLS001 for a cor
- Schwind Eye-Tech-Solutions Announces Management Changeshttps://modernod.com/news/schwind-eye-tech-solutions-announces-management-changes/2481149/Rolf Schwind, who was serving as CEO of Schwind eye-tech-solutions GmbH, has withdrawn from active leadership of the company, effective October 1, 2022, and joined the Advisory Board. In that capacity he will continue to contribute to the growth of Schwind with his more than 40 years of
- Harrow Announces FDA Approval of Iheezo for Ocular Surface Anesthesiahttps://modernod.com/news/harrow-announces-fda-approval-of-iheezo-for-ocular-surface-anesthesia/2481122/Harrow and Sintetica SA jointly announced the FDA approval of Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. Iheezo is a sterile, single-patient‑use, physician‑administered, ophthalmic gel preparation, containing no preservatives, that i
- Johnson & Johnson Vision Launches Acuvue Oasys Max 1-Dayhttps://modernod.com/news/johnson-johnson-vision-launches-acuvue-oasys-max-1-day/2481083/Johnson & Johnson Vision Care announced the launch of its newest innovation, Acuvue Oasys Max 1-Day contact lenses and Acuvue Oasys Max 1-Day Multifocal contact lenses for presbyopia. The lenses are designed with a combination of new technologies to help meet the needs of digit
- Neurolens Raises $67 Million Investment to Develop New Products and Accelerate Adoptionhttps://modernod.com/news/neurolens-raises-67-million-investment-to-develop-new-products-and-accelerate-adoption/2481080/Neurolens announced completion of a $67 million financing to fuel continued product innovation and growth initiatives, further accelerating the adoption of Neurolens. The financing was led by MVM Partners, with additional participation from Falcon Vision/KKR, Marshall Wac
- TearLab Announces Corporate Name Change to Trukera Medical; Targets Corneal Healthhttps://modernod.com/news/tearlab-announces-corporate-name-change-to-trukera-medical-targets-corneal-health/2481067/TearLab announced that it will be expanding its position in corneal health under the new name Trukera Medical. The rebranding reflects the company’s vision and future growth strategy targeting a broader set of unmet needs across corneal health. “We continue to rema